Results 81 to 90 of about 8,451 (198)

The National Health and Medical Research Council Research Impact Indicators: Unveiling Omissions and Blind Spots, and Positioning for Change

Health Promotion Journal of Australia, Volume 37, Issue 4, October 2026.
ABSTRACT Issue Addressed This study assesses how the concept of (health) research impact has been operationalised in National Health and Medical Research Council (NHMRC) Impact Case Studies, and if and how lived experience research priorities have been considered, to ascertain implications for Australian health and medical research.
Nizam Abdu, Maria Unwin, Caroline Robertson, Oliver Black (Anaiwan), Victoria J. Palmer, Amanda J. Wheeler, Amanda L. Neil   +6 more
wiley   +1 more source

Mucosal‐Associated Invariant T Cells in Health and Disease

MedComm, Volume 7, Issue 10, October 2026.
The roles of MAIT cells in health and disease and their therapeutic applications. In healthy individuals, riboflavin metabolites secreted by commensal bacteria at mucosal sites are presented by MR1, leading to the activation of MAIT cells. Activated MAIT cells can maintain the barrier integrity of mucosal tissues in a steady state or migrate to the ...
Yu Zhao, Feng‐Mi Ou, Dan Liang, Yang Gao, Qing‐Qing Li, Yi‐Qun Kuang   +5 more
wiley   +1 more source

Updates in COPD Management: From Inflammatory Pathways to Targeted Therapies

European Journal of Clinical Investigation, Volume 56, Issue 10, October 2026.
COPD is a heterogeneous disease driven by overlapping neutrophilic and eosinophilic inflammatory pathways. This review highlights the shift from symptom‐based treatment toward phenotype‐ and biomarker‐directed care. Blood eosinophils, FeNO, and IgE predict corticosteroid responsiveness and identify candidates for biologic therapy.
Sasha Raman, Sreya Rahman, Francesca Polverino, Muhammad Adrish   +3 more
wiley   +1 more source

The effects of mepolizumab on exacerbation rates.

, 2013
The effects of mepolizumab on exacerbation rates.
Yao Liu (173014), Shu-juan Jiang (395395), Song Zhang (180477), Dao-wei Li (395394)   +3 more
core   +1 more source

Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study

Journal of Asthma and Allergy, 2019
Jean-Pierre Llanos,1 Christopher F Bell,1 Elizabeth Packnett,2 Ellen Thiel,2 Debra E Irwin,2 Beth Hahn,1 Hector Ortega3 1Respiratory, US Medical Affairs, GSK, Research Triangle Park, NC, USA; 2Truven Health Analytics, An IBM Watson Health Company, Ann ...
Llanos JP, Bell CF, Packnett E, Thiel E, Irwin DE, Hahn B, Ortega H   +6 more
doaj  

Retention of a Patency Capsule Shell in a Nonsteroidal Anti‐Inflammatory Drug‐Induced Small‐Bowel Stricture, Detected and Retrieved by Balloon‐Assisted Enteroscopy: Emphasizing the Importance of Confirming Capsule Excretion

Journal of Digestive Diseases, EarlyView.
Shinichiro Kawatoko, Tomohiro Nagasue, Akihiro Shigemori, Akihiro Yoshida, Junji Umeno   +4 more
wiley   +1 more source

Extent of Sinus Surgery Is Associated With Disease Control in Biologic Treated Type 2 Dominant CRS

International Forum of Allergy &Rhinology, Volume 16, Issue 9, Page 986-995, September 2026.
ABSTRACT Background A greater benefit of biologics is observed after surgery in Type 2 chronic rhinosinusitis with nasal polyps (CRSwNP). However, the extent of surgery remains undefined in many studies. This study evaluated the extent of surgery on disease control in patients receiving biologics for refractory Type 2 dominant CRSwNP.
Nicholas J. Campion, Peta‐Lee Sacks, Lu Hui Png, Ruoxin Hua, Rhea Darbari Kaul, Raquel Alvarado, Christine Choy, Raymond Sacks, Peter Earls, Raewyn G. Campbell, Larry Kalish, Richard J. Harvey   +11 more
wiley   +1 more source

Table1_A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system.DOCX

, 2023
Background: Mepolizumab has been approved by the FDA for add-on maintenance treatment of severe asthma with an eosinophilic phenotype. Real-world studies on mepolizumab-associated adverse events are limited. The present study aimed to explore mepolizumab-
Cuilian Guo (17595876), Chongshu Wang (17595873), Aiping Deng (3070284), Huqun Li (3545402)   +3 more
core   +1 more source

Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy

, 2018
Paola Faverio,1,2 Giulia Bonaiti,1,2 Francesco Bini,3 Adriano Vaghi,3 Alberto Pesci1,2 1School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; 2Respiratory Unit, San Gerardo Hospital, ASST di Monza, Monza, Italy; 3ASST-Rhodense, UOC
Bini F, Vaghi A, Faverio P, Pesci A, Bonaiti G   +4 more
core  

Eosinophilia Reflects Type 2 Immune Activation in Newly Diagnosed Bullous Pemphigoid, With No Evidence of Charcot‐Leyden Crystals

Allergy, EarlyView.
Janik Fleißner, Tassilo Dege, Sandrine Benoit, Matthias Goebeler, Andreas Kerstan   +4 more
wiley   +1 more source